Evidence map›Paper›PMID 34513734›Full record

ArticleFrontiers in cellular and infection microbiology2021

An Innovative Protocol for Metaproteomic Analyses of Microbial Pathogens in Cystic Fibrosis Sputum.

Alexander C Graf, Johanna Striesow, Jan Pané-Farré, Thomas Sura, Martina Wurster, Michael Lalk, Dietmar H Pieper, Dörte Becher, Barbara C Kahl, Katharina Riedel

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. A Pilot Study ofDiagnostics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Microbiome analysis of Cystic Fibrosis sputum presents higher sensitivity than the conventional bacterial culture.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Alexander C GrafInstitute of Microbiology, Department of Microbial Physiology & Molecular Biology, University of Greifswald, Greifswald, Germany.
Johanna StriesowResearch Group ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology, Greifswald, Germany.
Jan Pané-FarréCenter for Synthetic Microbiology, Department of Chemistry, Philipps-University Marburg, Marburg, Germany.
Thomas SuraInstitute of Microbiology, Department of Microbial Proteomics, University of Greifswald, Greifswald, Germany.
Martina WursterInstitute of Biochemistry, Department of Cellular Biochemistry & Metabolomics, University of Greifswald, Greifswald, Germany.
Michael LalkInstitute of Biochemistry, Department of Cellular Biochemistry & Metabolomics, University of Greifswald, Greifswald, Germany.
Dietmar H PieperResearch Group Microbial Interactions and Processes, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Dörte BecherInstitute of Microbiology, Department of Microbial Proteomics, University of Greifswald, Greifswald, Germany.
Barbara C KahlInstitute of Medical Microbiology, University Hospital Münster, Münster, Germany.
Katharina RiedelInstitute of Microbiology, Department of Microbial Physiology & Molecular Biology, University of Greifswald, Greifswald, Germany.
Universität Greifswald · DEHelmholtz Centre for Infection Research · DELeibniz Institute for Plasma Science and Technology · DELoewe Center for Synthetic Microbiology · DEUniversity Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hallmarks of cystic fibrosis (CF) are increased viscosity of mucus and impaired mucociliary clearance within the airways due to mutations of the cystic fibrosis conductance regulator gene. This facilitates the colonization of the lung by microbial pathogens and the concomitant establishment of chronic infections leading to tissue damage, reduced lung function, and decreased life expectancy. Although the interplay between key CF pathogens plays a major role during disease progression, the pathophysiology of the microbial community in CF lungs remains poorly understood. Particular challenges in the analysis of the microbial population present in CF sputum is (I) the inhomogeneous, viscous, and slimy consistence of CF sputum, and (II) the high number of human proteins masking comparably low abundant microbial proteins. To address these challenges, we used 21 CF sputum samples to develop a reliable, reproducible and widely applicable protocol for sputum processing, microbial enrichment, cell disruption, protein extraction and subsequent metaproteomic analyses. As a proof of concept, we selected three sputum samples for detailed metaproteome analyses and complemented and validated metaproteome data by 16S sequencing, metabolomic as well as microscopic analyses. Applying our protocol, the number of bacterial proteins/protein groups increased from 199-425 to 392-868 in enriched samples compared to nonenriched controls. These early microbial metaproteome data suggest that the arginine deiminase pathway and multiple proteases and peptidases identified from various bacterial genera could so far be underappreciated in their contribution to the CF pathophysiology. By providing a standardized and effective protocol for sputum processing and microbial enrichment, our study represents an important basis for future studies investigating the physiology of microbial pathogens in CF

Indexed as

Cystic FibrosisMicrobiotaBacteriaHumansLungSputum16S sequencingcystic fibrosisin vivometabolomicsmetaproteomicsmicrobial communitymicrobiomesputum

Identifiers

PMID34513734
PMCPMC8432295
OpenAlexW3198827253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.